Montpellier, September 21th 2023 - French medical robotics company Quantum Surgical has obtained market authorization from the National Medical Products Administration(NMPA) for the use and commercialization of its Epione® robot in China. Epione enables early and minimally invasive treatment of abdominal tumors. Nearly 610,000 new cases are diagnosed in China each year

‍

Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.  

Epione® can be used to treat abdominal tumors (including the liver, kidneys, and pancreas) and over 200 patients have already been treated in France and the United States.

The NMPA market authorization allows for offering this innovative, better targeted,and minimally invasive treatment to new patients in China, where nearly 610,000new cases of abdominal cancers are diagnosed each year.

"Thanks to the NMPA market authorization, we are very excited to be able to offer our Epione® solution to interventional oncologists in China. This is an important step that will provide Chinese patients with an innovative and minimally invasive treatment to treat their abdominal tumors at an early stage, while improving their comfort" says Bertin Nahum, President and Co-founder of Quantum Surgical.

"TheNMPA market authorization confirms the effectiveness of Epione® and, above all, the relevance of its deployment in China, where nearly 610,000 cases of abdominal cancers are diagnosed each year" explains Laetitia Messner, Chief Clinical Officer of Quantum Surgical.

Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, anavigation system and a camera.

Percutaneous ablation is an alternative to surgery in which a needle is inserted throughthe skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or their location.

Relying on the know-how of the physician, Epione® integrates all the steps of a percutaneous ablation procedure in a single platform: planning, targeting, ablation, confirmation.

[1] Globocan, 2020

Montpellier, December 11^th 2023 – Popular Equipment Finance (DBA K2 Capital Group), a leader in equipment financing solutions in the US, has acquired Quantum Surgical’s Epione® robot. Popular Equipment Finance (DBA K2 Capital Group)works with top healthcare organizations across the U.S, including the renowned Cancer Center where Epione® was used in May 2023 to treat the first cancer patient in the territory.

The Epione® robotic platform is dedicated to the curative and early treatment of inoperable tumors in the abdomen (including liver, kidney and pancreas). A renowned cancer center in the US started using Epione® in May 2023 and has now entered a lease agreement with K2.

"It's very exciting that our group is the first in the Americas to use Epione® to treat abdominal tumors bringing such cutting-edge technology to mainstream clinical practice. The robot's accuracy is remarkable; we have shortened procedures times for complicated procedures and reduced radiation exposure for both the patient and the physician. Epione® is now part of our standard protocol for ablating abdominal tumors.” says Dr. Govindarajan Narayanan.

"The entire Quantum Surgical team is thrille dabout this first acquisition in the United States. Patient treatment and customer satisfaction are our priorities, and we are very proud of the positive feedback we’ve received from our users, which will help accelerate Epione®’s adoption in the US territory” says Bertin Nahum, President and Co-founder of Quantum Surgical.

As a reminder, Epione® is a robot-assisted technology designed to plan, target, perform, and confirm tumor ablation in the abdomen. Epione® allows physicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which one or more needles are inserted through the skin to the tumor to destroy it.

Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is also available at the Gustave Roussy Cancer Center in Villejuif, as well as at the Hospices Civils de Lyon. Over 300 patients have already been treated worldwide.

‍

Montpellier, September 7^th 2023 – French medical robotics company Quantum Surgical has obtained CE mark approval for the expanded use of its robotic platform, Epione®, in the treatment of lung tumors. With over 2 million new cases worldwide in 2020, including approximately500,000 in Europe, lung cancer is the leading cause of cance- related mortality[1]. This new feature will be presented with related clinical study results at the CIRSE 2023 conference in Copenhagen from September 9th to 13th by Dr. Bonnet, interventional radiologist at Gustave Roussy.

Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allow sphysicians to treat inoperable tumors that are particularly difficult to reach,due to their size or their location, at an early stage, in a simple and effective way.  

Epione® can be used to treat abdominal tumors (including theliver, kidneys, and pancreas) and over 200 patients have already been treated inFrance and the United States.

The CE mark approval for lung tumors will expand thisinnovative, targeted, and minimally invasive treatment to new patients inEurope.

It is based on a clinical study conducted at Gustave Roussy, the leading cancer center in Europe (third worldwide), the results of which will be presented during the international scientific conference organized by CIRSE(Cardiovascular and Interventional Radiological Society of Europe).

"With Epione®, our goal is to provide patients with an effective, better targeted and minimally invasive treatment. While over 2 million new cases of lung cancer diagnosed each year worldwide, we are delighted that our technology can now be accessible to new patients in Europe" said Bertin Nahum, President and Co-founder of Quantum Surgical.

“Patients were treated at Gustave Roussy with thermal destruction of lung metastases as part of a clinical study investigating the feasibility and safety of robotic guidance. In this ongoing study, the Epione® robot has consistently enabled technical success and has proven to be safe. The Epione® robot could enhance the minimally nvasive management of small and hard-to-reach lung tumors," stated Professor Thierry De Baère, Interventional Radiologist in the Department of Therapeutic Imaging at Gustave Roussy and member of the scientific advisory board of Quantum Surgical.

Laetitia Messner, Chief Clinical Officer of Quantum Surgical, explains, "Coordinated by Professor De Baère, the clinical study has demonstrated the clinical performance and safety of Epione® in the treatment of lung tumors. The CE mark approval proves the relevance and effectiveness of Epione®, which will enable us to offer innovative, targeted, and less invasive treatments to new patients."

Epione® is a robotic-assisted percutaneous ablation system, using a robotic arm, a navigation system and a camera. This procedure is an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This technique makes it possible to treat tumors that are particularly difficult to reach, due to their size or theirl ocation.

Relying on the know-how of the practitioner,Epione® integrates all the steps of a percutaneous ablation procedure in asingle platform: planning, targeting, ablation, confirmation.

[1] Globocan 2020

‍

Montpellier, June 13, 2023 – A 50th patient has been treated using the Epione® robot from Quantum Surgical by the team of Pr. Laurent Milot, Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon (France), highlighting a successful collaboration only 8 months post-acquisition.

Installed in November 2022, the team of the Hospices Civils de Lyon (HCL, France) are convinced of the value of this innovative platform from Quantum Surgical and celebrating that 50 patients have benefited from Epione®.Epione® can be used to treat early-stage abdominal tumors that are inoperable or particularly difficult to reach, due to their size or location.

HCL is the second hospital in the world offering this revolutionary platform to their patients. The first Epione® robot was acquired by the Institut Gustave Roussy (France) in January 2022 where the team has already treated more than 100 patients. The very first patient in the United States was also successfully treated using the Epione® robot at Baptist Hospital in Miami (Florida) last month.

Beyond the new procedural advantages it provides, Epione® makes it possible to offer patients a minimally invasive treatment. It improves their comfort and facilitates their recovery, due to the absence of surgery.

For physicians and hospitals, Epione® combines advanced robotic assistance with image-guided navigation and ablation confirmation tools to promote the standardization of minimally invasive tumor ablation procedures. This is a major challenge given that more than 4 million abdominal cancers are diagnosed each year in the world[1].

“I am very pleased with this milestone, which above all underlines the perfect match between the HCL teams and the Epione® robot, which delivers all its promises. We are very excited to continue to explore the many benefits of Epione® and to support the next steps in the development of robotics in interventional radiology. This will undoubtedly lead to significant progress and extend hope for patients we do not have treatment solutions for so far” explains Prof. Laurent Milot, Deputy Chief Vascular & Interventional Radiology.

“The implementation of the Epione® robot within the Hospices Civils de Lyon is a success: in eight months, 50 patients have already benefited from our technology, as part of their cancer treatment. Pr. LaurentMilot's teams are particularly enthusiastic. We are delighted with this collaboration, which improves access to care and patient comfort” said Bertin Nahum, president and co-founder of Quantum Surgical.

[1] Source: GlobalCancer Observatory

Montpellier, May 24, 2023 – Dr. Govindarajan Narayanan, chief of interventional oncology at Miami Cancer Institute and a vascular interventional radiologist with Miami Cardiac & Vascular Institute, successfully treated the first patient in the US with a liver tumor using Quantum Surgical’s Epione® robot. The procedure took place at Baptist Health South Florida in Miami, Florida, a few days after the Food and Drug Administration cleared Epione® robot for treatment of all abdominal cancers.

Quantum Surgical’s flagship product, the Epione® robotic platform, is dedicated to the curative treatment of cancers. Epione® allows physicians to treat inoperable tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.  

More than 150 patients have already been treated with the Epione® robot in Europe, and Dr. Narayanan successfully treated the first patient in the US.

“I am honored to be the first physician to utilize Epione® in the United States as this robotic-assisted equipment is going to change the way we deliver effective treatments to our patients for cancerous tumors,” said Dr. Narayanan. “Baptist Health has always been at the forefront when it comes to providing the very best care to the South Florida community and beyond. I am proud to be a part of such an incredible team.”

"We are very proud of this first intervention with our Epione® robot in the US! We are delighted to have been able to work with Dr. Narayanan and Baptist Health South Florida, renowned experts. This first intervention coincides with the FDA extension clearance to deploy our robotic solution in the United States. Dr. Narayanan is paving the way for physicians who will be able to offer more patients to benefit from innovative and less invasive treatments, and improve their lives" declares Bertin Nahum, President and co-founder of Quantum Surgical.

Epione® is a robot-assisted technology designed to plan, target, perform and confirm tumor ablation. Epione® enables physicians to perform percutaneous tumor ablations, a minimally invasive treatment in which one or more needles are inserted through the skin into the tumor to destroy it.

Epione® is currently available in Europe and the United States for treatment of all abdominal cancers. More than 4 million abdominal cancers occur each year worldwide[1].

[1] Source: Global Cancer Observatory

‍